CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 25, 2010
Result type: Reports
Project Number: SR0212-000
Product Line: Reimbursement Review

Generic Name: Lacosamide

Brand Name: Vimpat

Manufacturer: UCB Canada Inc.

Therapeutic Area: Epilepsy, partial onset seizures

Indications: Epilepsy, partial onset seizures (POS)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 25, 2011

Recommendation Type: List with clinical criteria and/or conditions